-
公开(公告)号:CA3005052A1
公开(公告)日:2017-05-18
申请号:CA3005052
申请日:2016-11-11
Applicant: MICROOPTX INC
Inventor: MARTIN ROY CHRISTIAN , PULLING CHRISTOPHER CLARK , MARTIN CHRISTOPHER THOMAS , BROWN J DAVID
IPC: A61B3/12 , A61B5/1455 , A61B5/1459
Abstract: A method for monitoring glucose concentration in aqueous humor can include inserting an implantable device into an eye and determining glucose concentration as a function of glucose sensed at the implantable device. The method can optionally include optically detecting glucose concentration as a function of polarimetry and/or fluorescence. A system for monitoring glucose concentration can include devices described herein.
-
公开(公告)号:EP3240510A2
公开(公告)日:2017-11-08
申请号:EP15876235.1
申请日:2015-12-30
Applicant: Microoptx Inc.
Inventor: BROWN, J., David
IPC: A61F9/007
CPC classification number: A61F9/00781 , A61F2220/0016 , A61F2220/0033 , A61F2250/006 , A61L27/18 , A61L27/28
Abstract: Devices can be implanted in an eye to treat glaucoma. The devices described herein include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. By the strategic selection of particular materials of construction, and/or by controlling the configuration and size of the lumen, in some embodiments, the device is a filterless construct. In some embodiments, a filter is included. The glaucoma treatment devices as provided herein are designed to prevent bacterial ingress and to provide the required level of outflow resistance to achieve a desired intraocular pressure. Methods of treating glaucoma wherein the device is implanted in the sclera of an afflicted eye are also described.
-
公开(公告)号:EP3355983A1
公开(公告)日:2018-08-08
申请号:EP16852726.5
申请日:2016-09-30
Applicant: Microoptx Inc.
Inventor: BROWN, J. David
CPC classification number: A61F9/0017 , A61F9/00781 , A61F2220/0008 , A61K31/25 , A61L31/06 , A61L31/10 , A61L2420/00
Abstract: Devices can be implanted in an eye to treat a dry eye condition. The devices include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. In some embodiments, the device is filterless. In some embodiments, a filter is included. The dry eye treatment devices provided herein prevent bacterial ingress, provide outflow resistance to retain a normal intraocular pressure, and provide moisture (e.g., aqueous humor) to an otherwise dry eye. Methods of treating a dry eye condition wherein the device is implanted in the sclera of an afflicted eye are also described.
-
公开(公告)号:EP3941399A1
公开(公告)日:2022-01-26
申请号:EP20774799.9
申请日:2020-03-20
Applicant: Microoptx Inc.
Inventor: COHEN, Edward Aaron , VOCE, Daniel Charles
-
公开(公告)号:EP3724650A1
公开(公告)日:2020-10-21
申请号:EP18888956.2
申请日:2018-12-04
Applicant: Microoptx Inc.
Inventor: COHEN, Edward Aaron , MARTIN, Roy Christian
IPC: G01N27/327 , A61B5/145 , A61B5/00
-
公开(公告)号:EP3494151A1
公开(公告)日:2019-06-12
申请号:EP17837666.1
申请日:2017-08-03
Applicant: Microoptx Inc.
Inventor: PAN, Tingrui , COHEN, Edward Aaron , BAZOR, Ben , YANG, Gaomai
IPC: C08F287/00 , C08F291/00 , C08F265/04 , C08F265/02 , C08F265/00 , C08F293/00 , C08J7/18 , C08J7/12 , C08J7/06 , C08J7/04 , C08J7/16
-
公开(公告)号:EP3481453A1
公开(公告)日:2019-05-15
申请号:EP17824818.3
申请日:2017-07-05
Applicant: Microoptx Inc.
-
公开(公告)号:EP3373797A1
公开(公告)日:2018-09-19
申请号:EP16865059.6
申请日:2016-11-11
Applicant: Microoptx Inc.
Inventor: MARTIN, Roy Christian , PULLING, Christopher Clark , MARTIN, Christopher Thomas , BROWN, J. David
IPC: A61B3/12 , A61B5/1455 , A61B5/1459
CPC classification number: A61B5/14532 , A61B5/14507 , A61B5/1455 , A61B5/1459 , A61B5/6821 , A61B5/686
Abstract: A method for monitoring glucose concentration in aqueous humor can include inserting an implantable device into an eye and determining glucose concentration as a function of glucose sensed at the implantable device. The method can optionally include optically detecting glucose concentration as a function of polarimetry and/or fluorescence. A system for monitoring glucose concentration can include devices described herein.
-
-
-
-
-
-
-